Charles River Laboratories (CRL)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
$228.72-1.17%
Close 2026-07-07 · 1-day change
Reading CRL? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CRL free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
Reading CRL? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CRL free→QuarterlyIQ Insights · CRL
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
The filing is about the approval of a new long-term incentive plan, not a management change.
Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On May 7, 2026, Charles River Laboratories International, Inc. issued a press release providing financial re…
Regulation FD Disclosure The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Planned Divestiture of CDMO and Cell Solutions Businesses On February 25, 2026, Charles River Laboratories International, Inc. (t…
Corporate Executive Vice President and Chief Financial Officer — Glenn Coleman: The company is hiring a new CFO with extensive experience in the healthcare sector.
Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On February 18, 2026, Charles River Laboratories International, Inc. issued a press release providing financ…
Regulation FD Disclosure The Slide Presentation prepared in connection with the J.P. Morgan Conference also includes the following statements as to recent client demand trends and preliminary 2026 outlook: • Q4 DSA Trends: DSA demand trends continued to improve throughout the second half of 2025, resulting in preliminary DSA net book-to-bill of approximately 1.1x in the fourth quarter of 2025 – Improving trends during the second half of 2025 were primarily driven by small and mid-sized biotec…
above shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing. This Current Report on 8-K contains a forward-looking, non-GAAP financial measure: non-GAAP e…
CEO — James C. Foster: Mr. James C. Foster is stepping down as CEO and Chairman, with Ms. Birgit Girshick appointed as the new CEO.
Regulation FD Disclosure The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Charles River Laboratories International, Inc. (“Charles River”, the “Company”, or the “Registrant”) is presenting at the Evercor…
Other Events As previously disclosed, on May 16, 2023, Charles River Laboratories International, Inc., (Company) received an inquiry from the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) requesting it to voluntarily provide information, subsequently augmented with a document subpoena and additional inquiries, primarily related to the sourcing of non-human primates and related disclosures. In addition, the Company’s Audit Committee retained counsel to conduct an in…
Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On November 5, 2025, Charles River Laboratories International, Inc. issued a press release providing financi…
Chief Financial Officer — Flavia H. Pease: The CFO resigned and an interim CFO was appointed.
Regulation FD Disclosure On September 16, 2025, the Company issued a press release announcing Ms. Pease’s departure and Mr. Knell’s appointment. A copy of the press release is attached as Exhibit 99.1 hereto. The press release, attached as an exhibit to this report, includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the press release are "forward-looking" rather than historic. The press…
Chief Financial Officer — Flavia H. Pease: Ms. Pease resigned from her position as Chief Financial Officer.
Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On August 6, 2025, Charles River Laboratories International, Inc. issued a press release providing financial…
James C. Foster: The employment term of the CEO was extended by an additional year.
Director — Robert Bertolini, Deborah T. Kochevar, George E. Massaro, Richard F. Wallman: Four directors decided not to stand for re-election at the annual meeting.
Entry into a Material Definitive Agreement. On May 6, 2025 (the “Effective Date”), Charles River Laboratories International, Inc. (the “Company”) entered into a Cooperation Agreement (the “Cooperation Agreement”) by and among Elliott Investment Management L.P., a Delaware limited partnership, Elliott Associates, L.P., a Delaware limited partnership and Elliott International, L.P., a Cayman Islands limited partnership (each, an “Elliott Party,” and collectively, the “Elliott Parties”). Pursuan…
Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On May 7, 2025, Charles River Laboratories International, Inc. issued a press release providing financial re…
Other Events Purchase of Shares of Company Common Stock On February 20, 2025: • Mr. James C. Foster, Chair, President and Chief Executive Officer of Charles River Laboratories International, Inc. (the “Company”) purchased 6,075 shares of the Company’s common stock at an average price of $165.01 for an aggregate purchase price of approximately $1 million in open market transactions. • Ms. Birgit Girshick, Corporate Executive Vice President and Chief Operating Officer of the Company purchased 1…
Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On February 19, 2025, Charles River Laboratories International, Inc. issued a press release providing financ…
Regulation FD Disclosure The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Charles River Laboratories International, Inc. ("Charles River", the "Company", or the “Registrant”) will be presenting at the 43…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On December 13, 2024, Charles River Laboratories International, Inc. (“Charles River”) amended and restated its existing credit agreement with certain financial institutions and JPMorgan Chase Bank, N.A., as administrative agent (the “Tenth Amended and Restated Credit Agreement”). The Tenth Amended and Restated Credit Agreement (1) extends the maturity date for the facilities, (2…
Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On November 6, 2024, Charles River Laboratories International, Inc. issued a press release providing financi…
Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On August 7, 2024, Charles River Laboratories International, Inc. issued a press release providing financial…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.